Literature DB >> 21144368

Silicone intubation and endoscopic dacryocystorhinostomy: a meta-analysis.

Zhaowei Gu1, Zhiwei Cao.   

Abstract

OBJECTIVES: during endoscopic dacryocystorhinostomy (En-DCR), bicanalicular insertion of silicone tubing into the lacrimal duct is the most common procedure to prevent the closure of the rhinostomy. It has been claimed that silicone tubing would improve the surgical outcomes of En-DCR. However, many reports revealed that without silicone intubation in En-DCR, the surgical success rate was equally high. The benefit of silicone intubation in En-DCR is controversial. Therefore, the aims of this study were to evaluate the outcome with or without the use of lacrimal silicone tubes in En-DCR and to identify whether silicone tubes after primary En-DCR are necessary.
METHODS: MEDLINE, EMBASE, Cochrane Library, and manual searches were conducted to identify all studies published in English between January 1, 1990, and October 30, 2009, on En-DCR with or without silicone intubation. Search terms included "endoscopic dacryocystorhinostomy" and "silicone intubation/intubing." We also reviewed references from all retrieved articles and performed a meta-analysis of the literature.
RESULTS: of four retrieved trials from the electronic database, two trials involving 84 patients met our inclusion criteria. There was no statistically significant heterogeneity between the studies. In the fixed-effects models, the pooled risk ratio was 0.85 and the 95% confidence interval was 0.71 to approximately 1.02.
CONCLUSION: the use of silicone tubes after primary En-DCR is not necessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144368

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


  12 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  [Indications and techniques for intubation of the lacrimal ducts].

Authors:  U Schaudig; P Heidari
Journal:  Ophthalmologe       Date:  2013-06       Impact factor: 1.059

3.  Endonasal dacryocystorhinostomy with and without stenting.

Authors:  M I Syed; J Hendry; A J Cain; A T Williams
Journal:  Ann R Coll Surg Engl       Date:  2014-03       Impact factor: 1.891

4.  Prognostic factors for outcome of endoscopic dacryocystorhinostomy in patients with primary acquired nasolacrimal duct obstruction.

Authors:  Shiu Ting Mak; Ida Yu-fong Io; Albert Chak-ming Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-19       Impact factor: 3.117

5.  Comparison of the extrusion rate of Crawford tubes.

Authors:  Kira L Segal; Sarah H Van Tassel; Charles Kim; Nicole Hsu; Ashutosh Kacker; Gary J Lelli
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

6.  Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article.

Authors:  Elina Penttilä; Grigori Smirnov; Henri Tuomilehto; Kai Kaarniranta; Juha Seppä
Journal:  Allergy Rhinol (Providence)       Date:  2015-01

7.  Authors' response.

Authors:  S Mohamad; I Khan; M Shakeel
Journal:  Ann R Coll Surg Engl       Date:  2014-03       Impact factor: 1.891

8.  Species-specific characteristics of the biofilm generated in silicone tube: an in vitro study.

Authors:  Dong Ju Kim; Joo-Hee Park; Minwook Chang
Journal:  BMC Ophthalmol       Date:  2018-04-03       Impact factor: 2.209

9.  Comparing the Success Rate of Dacryocystorhinostomy With and Without Silicone Intubation: A Trial Sequential Analysis of Randomized Control Trials.

Authors:  ChuanQi Xie; Lingling Zhang; Yang Liu; Hong Ma; Shuzhen Li
Journal:  Sci Rep       Date:  2017-05-16       Impact factor: 4.379

Review 10.  A Systematic Review of Benefit of Silicone Intubation in Endoscopic Dacryocystorhinostomy.

Authors:  Min Gyu Kang; Woo Sub Shim; Dong Keun Shin; Joo Yeon Kim; Ji-Eun Lee; Hahn Jin Jung
Journal:  Clin Exp Otorhinolaryngol       Date:  2018-04-14       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.